CYBIN INC (CYBN)

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Don't jump in without doing some research first.

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Strengthens Its Clinical Development Team

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports on Status of Key Clinical Milestones

Cybin Provides Corporate Update on Upcoming Clinical Milestones

Cybin Announces Completion of Previously Announced Share Consolidation

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Annual and Special Meeting of Shareholders, Share Consolidation

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

CYBN Stock Earnings: Cybin Beats EPS for Q1 2024

CYBN stock results show that Cybin beat analyst estimates for earnings per share the first quarter of 2024.

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

3 Biotech Stocks That Could Make Your Summer Unforgettable

If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.

Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)

Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns

Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.

3 Psychedelic Stocks to Buy on the Dip: Summer 2024

These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns.

CYBN Stock Earnings: Cybin Beats EPS for Q4 2023

CYBN stock results show that Cybin beat analyst estimates for earnings per share the fourth quarter of 2023.

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase